- Home
- AEVA vs STTK Comparison
AEVA vs STTK Comparison
Compare AEVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- STTK
- Stock Information
- Founded
- AEVA 2019
- STTK 2016
- Country
- AEVA United States
- STTK United States
- Employees
- AEVA N/A
- STTK N/A
- Industry
- AEVA Auto Parts:O.E.M.
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- STTK Health Care
- Exchange
- AEVA Nasdaq
- STTK Nasdaq
- Market Cap
- AEVA 241.9M
- STTK 56.8M
- IPO Year
- AEVA N/A
- STTK 2020
- Fundamental
- Price
- AEVA $4.17
- STTK $1.12
- Analyst Decision
- AEVA Buy
- STTK Hold
- Analyst Count
- AEVA 5
- STTK 3
- Target Price
- AEVA $10.53
- STTK $2.00
- AVG Volume (30 Days)
- AEVA 532.0K
- STTK 182.2K
- Earning Date
- AEVA 03-04-2025
- STTK 02-27-2025
- Dividend Yield
- AEVA N/A
- STTK N/A
- EPS Growth
- AEVA N/A
- STTK N/A
- EPS
- AEVA N/A
- STTK N/A
- Revenue
- AEVA $7,980,000.00
- STTK $6,435,000.00
- Revenue This Year
- AEVA $109.02
- STTK $313.04
- Revenue Next Year
- AEVA $63.91
- STTK N/A
- P/E Ratio
- AEVA N/A
- STTK N/A
- Revenue Growth
- AEVA 176.22
- STTK 382.75
- 52 Week Low
- AEVA $2.20
- STTK $0.94
- 52 Week High
- AEVA $7.25
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- AEVA 42.53
- STTK 43.75
- Support Level
- AEVA $4.08
- STTK $1.13
- Resistance Level
- AEVA $5.49
- STTK $1.39
- Average True Range (ATR)
- AEVA 0.40
- STTK 0.11
- MACD
- AEVA -0.08
- STTK 0.00
- Stochastic Oscillator
- AEVA 11.82
- STTK 18.18
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.